Firefly Reports 373% Increase In Pediatric ADHD Scan Volume As Platform Adotoption Grows
Firefly Neuroscience (AIFF) reported a 373% year-over-year increase in pediatric ADHD scans using its Evoke platform. The company attributes this growth to broader adoption across neuropsychiatric practices. Firefly also highlighted a partnership with NeuroSigma to offer the Monarch eTNS System, an FDA-cleared treatment for pediatric ADHD. AIFF's stock traded between $0.62 and $3.15 over the past year, closing Monday at $0.88.

